CD34 and acute lymphoblastic leukemia: To further investigate the specificity of the CD3CAR NK-92 cells in targeting primary leukemia patient samples, we considered a T-ALL patient sample expressing only a small subset of CD3+ T-cells, with a predominantly CD34+ CD3- tumor burden (Figure 3C).